



**ASX/Media Release**

**6 November 2019**

## **Receipt of second R&D Tax Incentive Rebate for FY2019**

**Melbourne, Australia; 6 November 2019:** Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received its R&D Tax Incentive Rebate from the Australian Taxation Office of \$1,513,637 for the 2019 financial year.

As announced 24 October 2019, an amount of \$501,605 was received by the Company’s 100% owned subsidiary Acrux Commercial Pty Ltd. The total rebate amount of \$2,015,242 for the 2019 financial year has therefore now been received.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

**For more information, please contact:**

### **General enquiries**

**Michael Kotsanis**  
**Acrux Limited**  
**CEO & Managing Director**

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

### **Investor enquiries**

**Joel Seah**  
**Vesparum Capital**

P: +61 3 8582 4800

E: acrux@vesparum.com

---

### **About Acrux**

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)